Surrogate and Composite Endpoints in Pharmaceutical Clinical Trials
Date: | 07-May-13 to 07-May-13 |
Location: | Online Event / California / United States |
Category: | Healthcare & Pharmaceuticals Conferences & Trade Fairs |
This training will review the regulatory definitions and correct implementation of composite and surrogate endpoints in pharmaceutical clinical trials. The program will compare these endpoints with traditional (direct) endpoints, summarizing the major advantages and challenges associated with them.
Visitors
CRAs and CRCs,Biostatisticians,Clinical trial QA,Documentation professionals
Exhibitors
Carolynn E Pietrangeli PhD., is an academic Immunologist with over two decades of experience working with the pharmaceutical industry, Dr. Pietrangeli has extensive experience with clinical trial planning, preparation of materials for the FDA and the education of industry personnel responsible for the execution of clinical trials. Therapeutic areas include solid organ and stem cell transplantation, hepatitis, HIV/AIDS, Alzheimer's disease, dermatology and autoimmune diseases.
EIN News
provides powerful, real-time media monitoring, news aggregation & syndication services. Read the latest news about this topic. See:
- Autism News Today
- Brain Cancer News Today
- Breast Cancer News Today
- Breastfeeding News Today
- Conferences & Trade Shows Today
- Dental Industry Today
- Dietary Supplements News Today
- H1N1 News Today
- H7N9 Bird Flu News Today
- Health Insurance Exchanges News
- Healthcare Industry Today
- Healthcare Reform News Today
- Home Birth News Today
- Lung Cancer News Today
- MERS News Today
- Malaria News Today
- Marijuana News Today
- Mesothelioma News Today
- Pharmaceutical Industry Today
- Planned Parenthood News Today
- Prostate Cancer News Today
- SARS News Today
- Wellness News Today